EUVIMEDEUVIMED entdecken
Open Access

1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis

Sonya Krishnan iD, Xingye Wu, Soyeon Kim, Katie McIntire, Linda Naini, Michael D Hughes, Rodney Dawson, Vidya Mave iD, Sanjay Gaikwad, Jorge Sanchez, Alberto Mendoza-Ticona, Pedro Gonzales und 15 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciad301 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Sonya Krishnan und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: HIV Infections, Latent Tuberculosis, Tuberculosis, Multidrug-Resistant, Tuberculosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NICHD NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tuberculosis infection (TBI) and TB disease (TBD) incidence remains poorly described following household contact (HHC) rifampin-/multidrug-resistant TB exposure. We sought to characterize TBI and TBD incidence at 1 year in HHCs and to evaluate TB preventive treatment (TPT) use in high-risk groups.

Methods

We previously conducted a cross-sectional study of HHCs with rifampin-/multidrug-resistant TB in 8 high-burden countries and reassessed TBI (interferon-gamma release assay, HHCs aged ≥5 years) and TBD (HHCs all ages) at 1 year. Incidence was estimated across age and risk groups (<5 years; ≥5 years, diagnosed with human immunodeficiency virus [HIV]; ≥5 years, not diagnosed with HIV/unknown, baseline TBI-positive) by logistic or log-binomial regression fitted using generalized estimating equations.

Results

Of 1016 HHCs, 850 (83.7%) from 247 households were assessed (median, 51.4 weeks). Among 242 HHCs, 52 tested interferon-gamma release assay–positive, yielding a 1-year 21.6% (95% confidence interval [CI], 16.7–27.4) TBI cumulative incidence. Sixteen of 742 HHCs developed confirmed (n = 5), probable (n = 3), or possible (n = 8) TBD, yielding a 2.3% (95% CI, 1.4–3.8) 1-year cumulative incidence (1.1%; 95% CI, .5–2.2 for confirmed/probable TBD). TBD relative risk was 11.5-fold (95% CI, 1.7–78.7), 10.4-fold (95% CI, 2.4–45.6), and 2.9-fold (95% CI, .5–17.8) higher in age <5 years, diagnosed with HIV, and baseline TBI high-risk groups, respectively, vs the not high-risk group (P = .0015). By 1 year, 4% (21 of 553) of high-risk HHCs had received TPT.

Conclusions

TBI and TBD incidence continued through 1 year in rifampin-/multidrug-resistant TB HHCs. Low TPT coverage emphasizes the need for evidence-based prevention and scale-up, particularly among high-risk groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsLatent TuberculosisTuberculosis, Multidrug-ResistantTuberculosisIron Metabolism DisordersCross-Sectional StudiesHumansIncidenceCataractRifampin

Stichwörter der Autor:innen

household contactsmultidrug-resistant tuberculosistuberculosis diseasetuberculosis infectiontuberculosis preventive treatment

Substanzen

Rifampin

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Frontier Science Foundation, Brookline, Massachusetts, USA.
  • Social & Scientific Systems, Silver Spring, Maryland, USA.
  • University of Cape Town Lung Institute and Department of Medicine, Cape Town, South Africa.
  • Byramjee Jeejeebhoy Government Medical College, Pune, India.

ORCID-Profile: Sonya Krishnan, Vidya Mave, Amita Gupta

Förderung

  • NIAID NIH HHS
  • NICHD NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • National Institute of Mental Health
  • AIDS Clinical Trials Group
  • NIH
  • Johns Hopkins University Baltimore-India Clinical Trials Unit

Zitieren

APA

Krishnan, S., Wu, X., Kim, S., McIntire, K., Naini, L., Hughes, M. D., Dawson, R., Mave, V., Gaikwad, S., Sanchez, J., Mendoza-Ticona, A., Gonzales, P., Comins, K., Shenje, J., Fontain, S. N., Omozoarhe, A., Mohapi, L., Lalloo, U. G., Garcia Ferreira, A. C., …, & AIDS Clinical Trials Group A5300/International Maternal Pediatric Adolescent AIDS Clinical Trials I2003 Protecting Households on Exposure to Newly Diagnosed In… (2023). 1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad301

Vancouver

Krishnan S, Wu X, Kim S, McIntire K, Naini L, Hughes MD, et al. 1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad301

BibTeX
@article{Krishnan2023,
  author = {Krishnan, Sonya and Wu, Xingye and Kim, Soyeon and McIntire, Katie and Naini, Linda and Hughes, Michael D and Dawson, Rodney and Mave, Vidya and Gaikwad, Sanjay and Sanchez, Jorge and Mendoza-Ticona, Alberto and Gonzales, Pedro and Comins, Kyla and Shenje, Justin and Fontain, Sandy Nerette and Omozoarhe, Ayotunde and Mohapi, Lerato and Lalloo, Umesh G and Garcia Ferreira, Ana Cristina and Mugah, Christopher and Harrington, Mark and Shah, N Sarita and Hesseling, Anneke C and Churchyard, Gavin and Swindells, Susan and Gupta, Amita and AIDS Clinical Trials Group A5300/International Maternal Pediatric Adolescent AIDS Clinical Trials I2003 Protecting Households on Exposure to Newly Diagnosed In…, AIDS Clinical Trials Group A5300/International Maternal Pediatric Adolescent AIDS Clinical Trials I2003 Protecting Households on Exposure to Newly Diagnosed In…},
  title = {1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciad301}
}
Kostenlos starten →